Neurodegenerative diseases represent an ever-increasing societal and economic burden with WHO estimates indicating that they will replace cancer as the 2nd leading cause of death by 2040. In neurodegenerative disease research, a wealth of pathways has been uncovered, but their direct and primary relevance to the respective human disease have been difficult to prove and pathways have remained difficult to target. For polyglutamine diseases, there is clear evidence that expression levels of the respective genes affect the phenotype and shutting-off expression in mouse models reverses already established motor phenotypes. We have chosen an autosomal dominant polyglutamine (polyQ) disease to demonstrate the proof-of-principle that small molecules can be used to downregulate expression of a disease gene at the transcriptional or mRNA stability level. Spinocerebellar ataxia type 2 (SCA2) is a multisystem neurodegenerative disease caused by a dominantly-acting mutation leading to expansion of a polyQ domain in the ataxin-2 protein. SCA2 patients develop progressive ataxia and later lose function in other neuronal systems. Prominent parkinsonian signs develop in some. Similar to many neurodegenerative disorders, no symptomatic or disease-modifying treatments are known. The primary objective of the proposed research is to identify compounds inhibiting ATXN2 expression and to test them for efficacy in SCA2 mouse models. To this end, we have developed a cell-based assay paired with an in vivo mouse model using identical luciferase expression constructs. This will allow us to progress compounds rapidly from a high-throughput screen conducted at NIH Chemical Genomics Center (NCGC) to efficacy and toxicity testing in mice.
Four specific aims are proposed: 1) HTS with 300,000 compounds at the NCGC, 2) In vitro testing of compounds in SCA2 patient lymphoblasts, 3) In vivo testing of compounds in ATXN2-luciferase transgenic mice, and 4) testing the ability for compounds to ameliorate an ATXN2 phenotype in a humanized SCA2 mouse BAC model. Our approach takes advantage of an ATXN2-luciferase transgene with luciferase gene flanked by the upstream and downstream portions of the ATXN2 gene. Mouse models are in place to test rapidly the efficacy of compounds in vivo including passage of the blood brain barrier, and further progression of compounds to test in mouse models with morphological, biochemical, and motor phenotypes replicating human SCA2. The proposed work will break new ground for treatment of neurodegenerative diseases by demonstrating feasibility of targeting dominant-acting mutated genes with compounds.
We aim to identify small molecules not only targeting gene expression levels, but also mRNA stability via the 3'-UTR. Our focus is on small molecules and extensive and rapid post HTS-testing in a number of rodent models as well as human cell lines.

Public Health Relevance

Neurodegenerative diseases are not only a major worldwide health problem, but owing to the large number affected and long course of illness, a significant economic threat. We are using SCA2, a debilitating and terminal disorder, as a model to examine novel approaches to identify disease-modifying compounds. Our approach of tightly coupling in vitro and in vivo screens can used to target other neurodegenerative diseases caused by dominant-acting gene mutations.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
High Impact Research and Research Infrastructure Programs—Multi-Yr Funding (RC4)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-A (55))
Program Officer
Gwinn, Katrina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Medicine
Salt Lake City
United States
Zip Code
Figueroa, Karla P; Gan, Shi-Rui; Perlman, Susan et al. (2018) C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias. Mov Disord 33:497-498
Paul, Sharan; Dansithong, Warunee; Figueroa, Karla P et al. (2018) Staufen1 links RNA stress granules and autophagy in a model of neurodegeneration. Nat Commun 9:3648
Scoles, Daniel R; Meera, Pratap; Schneider, Matthew D et al. (2017) Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544:362-366
Graf, Julia; Hellenbroich, Yorck; Veelken, Norbert et al. (2016) Two different genetic diseases in the same patient: Coincident, concomitant, or causally related? Mov Disord 31:491-2
Dansithong, Warunee; Paul, Sharan; Scoles, Daniel R et al. (2015) Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening. PLoS One 10:e0136930
Scoles, Daniel R; Ho, Mi H T; Dansithong, Warunee et al. (2015) Repeat Associated Non-AUG Translation (RAN Translation) Dependent on Sequence Downstream of the ATXN2 CAG Repeat. PLoS One 10:e0128769
Dansithong, Warunee; Paul, Sharan; Figueroa, Karla P et al. (2015) Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet 11:e1005182
Matilla-Dueñas, A; Ashizawa, T; Brice, A et al. (2014) Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum 13:269-302
Neuenschwander, Annalese G; Thai, Khanh K; Figueroa, Karla P et al. (2014) Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. JAMA Neurol 71:1529-34
Ashizawa, Tetsuo; Figueroa, Karla P; Perlman, Susan L et al. (2013) Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis 8:177

Showing the most recent 10 out of 12 publications